Hereditary Angioedema Treatment Market Trends

Hereditary Angioedema Treatment Market Drivers

Increased Emphasis on Advanced Therapeutics

• Researchers and manufacturers around the world are increasing their focus on advanced therapeutics for the treatment of hereditary angioedema disorders and taking the necessary steps to create or advance therapeutics for the treatment of hereditary angioedema disorders. Several manufacturers have recently filed new medication applications in various counties for C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor treatment of Type I, Type II, and Type III HAE. The increased emphasis on sophisticated treatments and innovative drug applications will increase the availability of hereditary angioedema treatment therapies during the forecast period.
• Its increased awareness and the rise in the occurrence of rare conditions around the world are important factors driving the global market. Novel medicine approvals in recent years, as well as promising pipeline drugs, have fuelled the expansion of the global market. Furthermore, the increased severity of severe edema attacks caused by elevated oestrogen levels, as well as the increased use of ACE inhibitors, are driving the expansion of the hereditary angioedema treatment market.

Hereditary Angioedema Treatment Market Restraint

• Misdiagnosis of the ailment as common allergies, appendicitis, and irritable bowel syndrome has caused treatment to be halted, hampering the growth of the hereditary angioedema treatment market. Lack of awareness regarding HAE is a primary cause of misdiagnosis, which leads to suboptimal treatment for patients. The majority of people with hereditary angioedema are misdiagnosed for appendicitis, gastrointestinal diseases, and other non-allergic angioedema. A large number of patients have been misdiagnosed with the illness.